Effects of Fingolimod (Gilenya) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients

Trial Profile

Effects of Fingolimod (Gilenya) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Status changed from recruiting to completed.
    • 14 Oct 2015 Planned end date changed from 1 Sep 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov.
    • 14 Oct 2015 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top